Effects of silodosin on sexual function – realistic picture from the everyday clinical practice

Summary The treatment with α1‐blockers in patients complaining of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) is associated with potential adverse events (AEs), thus including ejaculatory dysfunction (EjD). We sought to assess the effects of a 3‐month course of silodosin 8 mg daily dosing on sexual functioning, mainly including ejaculation and orgasm, in a cohort of 100 consecutive sexually active men in the real‐life setting. Patients completed the International Index of Erectile Function‐Orgasmic Function (IIEF‐OF) domain and the International Prostate Symptom Score (IPSS) both at baseline and at survey. Likewise, patients completed a 16‐item self‐administered questionnaire with closed questions also including specific questions regarding treatment‐related adverse events on sexual functioning. Rates and predictors of OF impairment and drug discontinuation were investigated. At survey, silodosin resulted highly effective in improving IPSS‐total and subscales (all p